Suzanne George Selected Research

Alopecia (Baldness)

3/2024	A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
12/2022	Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
10/2020	Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suzanne George Research Topics

Disease

52	Neoplasms (Cancer) 03/2024 - 11/2003
41	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2024 - 12/2002
29	Sarcoma (Soft Tissue Sarcoma) 05/2024 - 05/2007
18	Leiomyosarcoma 01/2024 - 04/2013
14	Disease Progression 01/2024 - 09/2007
7	Fatigue 03/2024 - 10/2006
6	Hypertension (High Blood Pressure) 01/2020 - 12/2007
5	Ewing Sarcoma (Sarcoma, Ewing) 12/2023 - 11/2014
4	Nausea 03/2024 - 10/2006
4	Diarrhea 03/2024 - 01/2011
3	Constipation 03/2024 - 10/2020
3	Alopecia (Baldness) 03/2024 - 10/2020
3	Alveolar Soft Part Sarcoma 01/2023 - 07/2015
3	Aggressive Fibromatosis (Desmoid) 12/2020 - 08/2012
3	Leiomyoma (Uterine Fibroids) 01/2016 - 05/2013
3	Stomatitis 06/2014 - 10/2011
3	Breast Neoplasms (Breast Cancer) 11/2012 - 11/2003
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2011 - 11/2006
2	Pneumonia (Pneumonitis) 03/2024 - 01/2022
2	Pain (Aches) 03/2024 - 10/2011
2	Exanthema (Rash) 03/2024 - 06/2014
2	Liposarcoma 01/2024 - 11/2023
2	Osteosarcoma (Osteogenic Sarcoma) 12/2023 - 11/2022
2	Anemia 11/2021 - 11/2014
1	Vomiting 03/2024
1	Epithelioid Hemangioendothelioma 03/2024
1	Edema (Dropsy) 03/2024
1	Hemangiosarcoma (Angiosarcoma) 01/2024
1	Bites and Stings (Sting) 01/2024
1	Pneumothorax 12/2023
1	Hypophosphatemia 01/2023
1	Fever (Fevers) 11/2022
1	Neoplasm Micrometastasis 11/2022
1	Injection Site Reaction 11/2022
1	Pulmonary Embolism 01/2022
1	Abdominal Pain (Pain, Abdominal) 11/2021
1	Myalgia 10/2020
1	Dehydration (Water Stress) 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020

Drug/Important Bio-Agent (IBA)

22	Imatinib Mesylate (Gleevec)FDA Link 02/2024 - 09/2007
18	Sunitinib (Sutent)FDA Link 01/2024 - 11/2006
15	Tyrosine Kinase InhibitorsIBA 11/2023 - 12/2002
14	Phosphotransferases (Kinase)IBA 02/2024 - 05/2006
12	ripretinibIBA 02/2024 - 01/2020
7	regorafenibIBA 01/2023 - 07/2012
7	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 10/2021 - 01/2011
6	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2024 - 04/2015
5	Biomarkers (Surrogate Marker)IBA 01/2024 - 10/2012
5	avapritinibIBA 11/2023 - 10/2020
4	Everolimus FDA Link 11/2023 - 02/2011
4	Tyrosine (L-Tyrosine)FDA Link 01/2023 - 12/2015
3	pembrolizumabIBA 01/2024 - 01/2017
3	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2017
3	DNA (Deoxyribonucleic Acid)IBA 09/2023 - 01/2019
3	tyrosine receptor (receptor, tyrosine)IBA 01/2023 - 01/2017
3	Circulating Tumor DNAIBA 01/2022 - 01/2019
3	Gemcitabine FDA Link 01/2019 - 05/2007
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2013
3	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 02/2008
2	PM 01183IBA 05/2024 - 01/2020
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2023 - 10/2017
2	olaparibIBA 01/2023 - 11/2014
2	VaccinesIBA 11/2022 - 07/2015
2	olaratumabIBA 01/2019 - 01/2017
2	mocetinostatIBA 01/2019 - 01/2018
2	Histone Deacetylase InhibitorsIBA 01/2018 - 04/2015
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 07/2015 - 09/2008
2	ridaforolimusIBA 04/2013 - 10/2011
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 07/2007 - 05/2006
1	Opiate AlkaloidsIBA 03/2024
1	trametinibIBA 03/2024
1	Adenosine Triphosphate (ATP)IBA 02/2024
1	eribulin FDA Link 01/2024
1	Topotecan (Hycamtin)FDA LinkGeneric 12/2023
1	cabozantinibIBA 12/2023
1	ribociclibIBA 11/2023
1	PlacebosIBA 11/2023
1	Temozolomide (Temodar)FDA LinkGeneric 01/2023
1	cediranib (AZD2171)IBA 01/2023
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2023
1	Immunoconjugates (Immunoconjugate)IBA 01/2023
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 11/2022
1	GangliosidesIBA 11/2022
1	AntibodiesIBA 11/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022
1	ponatinibIBA 01/2022
1	Immunoglobulin IsotypesIBA 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 10/2020
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2020

Therapy/Procedure

36	Therapeutics 01/2023 - 05/2006
9	Drug Therapy (Chemotherapy) 05/2024 - 10/2013
7	Radiotherapy 12/2020 - 09/2009
4	Immunotherapy 01/2019 - 01/2017
3	Drug Tapering 01/2023 - 10/2011
3	Morcellation 01/2016 - 10/2014
2	Aftercare (After-Treatment) 12/2022 - 05/2006
1	Precision Medicine 01/2023
1	Metastasectomy 11/2022
1	Duration of Therapy 11/2021